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Background
The Ebolavirus (EBOV) is extremely lethal with mortal-
ity rates ranging from twenty-three to ninety percent.
No licensed Ebola vaccine exists and classical protocols
for vaccine design do not comply. One solution, rational
vaccine design (RVD) is based on two parameters: (1.)
identification of epitopes, antigenic peptides that med-
iate the cellular immune system and (2.) exploitation of
the immune system’s ability to recognize and remember
vaccines.
Methods
To assess RVD feasibility, EBOV proteins were computa-
tionally analyzed for epitope identification. To evaluate
vaccine efficacy, mathematical models for virus dynamics
were simulated using MATLAB. Models relied on data
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Figure 1 (A) The trimeric Ebola Virus glycoprotein (silver) interacts with the light (orange) and heavy (green) chains of human antibody KZ52.
Purple boxes indicate sites of interactions, all of which are identical. (B) The EBOV GP epitope (purple) interacts with antibody loops at GP slits.
(C) Salt bridges stabilize epitope-antibody binding. Salt-bridge measurements from top to bottom are 3.41 Å, 2.77 Å, 3.24 Å, 3.35 Å, and 2.90 Å.
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from EBOV cultivation in cell-cultures, and were
extended with novel equations to consider memory B-
and T-cell production.
Results
First, RVD towards the EBOV is feasible. Computer-
based protein analysis identified novel EBOV peptides for
vaccine design. A key epitope –EAIVNAQPKCNPN…
MHNQDG– was extracted from a three-dimensional
structure of an EBOV protein bound to human antibody
KZ52. Secondly, vaccine efficacy can be assessed using
mathematical models. Multiple simulations of the models
revealed generally unknown parameters such as the virus’
birth and cellular infection rates. The models also quanti-
fied the cellular immune response necessary for vaccine
efficacy in an individual; the specifications of what the
vaccine must accomplish.
Conclusion
These results show that computer-aided RVD is feasible
and that mathematical models can establish RVD guide-
lines for the development of an EBOV vaccine.
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